On this pageJump to a section
"Same active ingredient as Wegovy. A fraction of the price."
You have seen an ad that reads something like that. It sounds helpful, it converts, and it is exactly the kind of sentence that gets a clinic into trouble. The product might be perfectly legal to dispense. The claim is the problem.
I am not a lawyer, and this is educational, not legal advice. I am an ad operator, and I have watched what happens when marketing runs ahead of what a clinic can actually support. Here is how I would sort the claims, starting with the one fact everything else hangs on.
What is the one fact every compounded GLP-1 ad has to respect?
Compounded drugs are not FDA-approved. That is not an opinion or a gotcha. It is how FDA describes them.
Compounded drugs do not undergo FDA premarket review for safety, quality or effectiveness.
FDA's page also says compounded drugs should be used only when an approved drug cannot meet a patient's medical needs.1 During a shortage, compounding can fill a gap, and that is the context clinics are operating in right now. But the shortage is a reason a product may be available. It is not a reason your ad can talk about it as if it were the brand-name product.
Why the status shapes the copy
Every sentence in an ad is either a statement about the clinic, a statement about the product or a statement about results. The FDA status limits the second and third. A clinic can say what it prescribes and who prescribes it. It cannot lend a compounded product the reputation of an approved one.
Which claims can a clinic usually support?
Claims about your own process are the safest, because you control the evidence.
| Claims you can usually support | Claims that invite regulators |
|---|---|
| Licensed clinicians review every intake | "Same as Wegovy" or "generic Ozempic" |
| A prescription is required after evaluation | "FDA-approved" about a compounded product |
| Dosing instructions and support are included | "Lose X pounds in Y weeks" as a promise |
| The product is compounded by a licensed pharmacy (if true) | "No side effects" or "completely safe" |
| Pricing and what it includes, stated plainly | Before and after photos presented as typical |
Be specific about what you are, and what you are not
Say that the medication is compounded, if it is. Say that compounded medications are not FDA-approved. A clinic that states this clearly looks more trustworthy to a careful buyer, and it protects you from the accusation that you hid it.
What do FTC rules say about weight loss and health claims?
The FTC's Health Products Compliance Guidance says health claims generally need competent and reliable scientific evidence, and it calls randomized controlled trials the most reliable form of evidence for health benefit claims. Observational studies can show an association but do not prove a causal link.2
Testimonials are claims too
The same guidance is blunt about testimonials. It is not enough that a testimonial reflects an honest opinion or experience, because individual experiences are not a substitute for scientific research, and a "results not typical" disclaimer does not cure a deceptive testimonial.2 If a patient's story implies a typical outcome you cannot back up, the story is the problem, even if every word is true.
Influencers and paid endorsements
If you pay creators or give free treatment in exchange for posts, the connection has to be disclosed. In June 2023 the FTC announced updated Endorsement Guides that cover fake and incentivized reviews and add detail on when and how to disclose a material connection, including on social media.5 An influencer who says "I lost weight with this clinic" and does not mention the payment has created two problems at once: the outcome claim and the hidden relationship.
Borrowing trial data
The best-known weight loss trial for semaglutide is STEP 1. In it, adults taking once-weekly semaglutide 2.4 mg lost a mean of 14.9% of body weight at 68 weeks, compared with 2.4% on placebo.4 That is a strong result for the approved product that was tested, and it is also a funding-disclosed result (Novo Nordisk paid for the trial). It is not evidence about a compounded product, which FDA has not reviewed. Quote the trial, if you quote it, as what it is: a trial of a different product. Better still, leave the numbers out of the ad.
How should an ad talk about dosing and safety?
Carefully, because this is where real harm has been reported.
FDA has received reports of adverse events, some requiring hospitalization, related to dosing errors with compounded injectable semaglutide. Most involved patients drawing up more than the prescribed dose from multiple-dose vials, sometimes five to 20 times the intended amount, and FDA says confusion between milliliters, milligrams and "units" may have contributed.1
An ad that promises a simple at-home injection without mentioning how dosing is taught is leaving out the part regulators are watching. The better move is to put your support in the copy: how patients are taught to measure, what syringe they receive and who they can call.
Why is price the claim everyone is tempted by?
Because the problem is real. KFF's May 2024 poll found 12% of US adults had ever taken a GLP-1 drug and 6% were currently taking one. Among people who had taken one, 54% said it was somewhat or very difficult to afford, and the list price was $936 to $1,349 before insurance, rebates or coupons.3
That pain is why price-led ads work, and why they get crowded as auction prices climb. It is also why price comparisons need discipline. Compare like with like, say what the price includes and avoid implying that a lower price means an identical product.
A review checklist before you publish
- List every claim in the ad and label it: about the clinic, the product or results.
- Remove any wording that implies equivalence with an approved brand.
- State clearly that the medication is compounded and not FDA-approved.
- Attach evidence to every outcome claim, or delete it.
- Treat testimonials as claims and review them the same way.
- Put dosing education and clinician support in the copy.
- Have your attorney review the final version.
The ad that makes you look the most careful is usually the ad that holds up longest.
If you run telehealth ads and want a plain-English second opinion on how your offer, intake and tracking fit together as one revenue path, I work on that at ekaistone.com. Compliance questions belong with your attorney.
Keep building.Ekai
Questions people ask
Is compounded semaglutide FDA-approved?
No. FDA states that compounded drugs do not undergo FDA premarket review for safety, quality or effectiveness. A clinic's ad should never describe a compounded product as FDA-approved.
Can a clinic say compounded semaglutide is the same as Wegovy or Ozempic?
It is the claim most likely to invite scrutiny. Approved products have been reviewed by FDA and compounded versions have not, so an equivalence claim is hard to substantiate. Describe what you actually provide instead.
Can I use clinical trial results in my ads?
Only with care. Published trials such as STEP 1 tested the approved semaglutide product, so the results belong to that product. Attributing them to a compounded product implies evidence that does not exist.
Do customer testimonials need a disclaimer?
A disclaimer helps but does not cure a misleading testimonial. FTC guidance says an honest personal experience is not enough on its own, and individual experiences are not a substitute for scientific evidence.
Sources
- 1
- 2
- 3
- 4
- 5
